We serve Chemical Name:2-Amino-3-iodopyridine CAS:104830-06-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-Amino-3-iodopyridine
CAS.NO:104830-06-0
Synonyms:MFCD01651885;2-Amino-3-iodopyridine;3-Iodopyridin-2-amine;2-Pyridinamine, 3-iodo-;(R)-(+)-1-Phenyl-1-propanol;3-Iodopyrid-2-ylamine
Molecular Formula:C5H5IN2
Molecular Weight:220.011
HS Code:2933399090
Physical and Chemical Properties:
Melting point:89-90°C
Boiling point:289.6±25.0 °C at 760 mmHg
Density:2.1±0.1 g/cm3
Index of Refraction:1.703
PSA:38.91000
Exact Mass:219.949738
LogP:2.02
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like MFCD01651885 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Iodopyrid-2-ylamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(R)-(+)-1-Phenyl-1-propanol Use and application,3-Iodopyridin-2-amine technical grade,usp/ep/jp grade.
Related News: In a memo to Branchburg employees on May 20, Nellie Clark, head of the plant, summed up the outside lawyers’ findings: “In the end and very importantly, allegations that Lilly made false statements to the FDA were not substantiated.” 2-Amino-3-iodopyridine manufacturer The results of analysis perfectly align with the tau hypothesis — simply put, if the patient is tau biomarker positive, then tau pathology is responsible for his/her cognitive decline, and halting tau pathology should slow or halt progression,” Novak said. “If the patient is negative for markers of tau pathology, then this patient’s impairment is mainly due to other pathologies, and treating tau pathology in this patient won’t be meaningful. 2-Amino-3-iodopyridine supplier Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world. 2-Amino-3-iodopyridine vendor ICIG is a privately owned industrial holding company focusing on mid-sized chemicals and pharmaceutical businesses. 2-Amino-3-iodopyridine factory The results of analysis perfectly align with the tau hypothesis — simply put, if the patient is tau biomarker positive, then tau pathology is responsible for his/her cognitive decline, and halting tau pathology should slow or halt progression,” Novak said. “If the patient is negative for markers of tau pathology, then this patient’s impairment is mainly due to other pathologies, and treating tau pathology in this patient won’t be meaningful.
